In a filing with the bourse, MYEG said the letter of intent was signed pursuant to its receipt of a letter of no objection from the government for the group to purchase Zhifei’s vaccine. The group said the letter of intent with Zhifei ensures that the corresponding quantity of the company’s recombinant protein subunit vaccine is reserved for delivery as early as August. “The cost of the vaccine will be determined later, subject to the conditional authorisation by NPRA,” said MYEG. Over 60 million doses of the vaccine have been administered in China, MYEG said, adding that the vaccine is also being used in Uzkbekistan. MYEG holds three-year rights to exclusively distribute the vaccine in Malaysia, as well as a two-year exclusive distribution rights to the vaccine in the Philippines.

Source: The Edge Markets June 25, 2021 13:34 UTC